95 related articles for article (PubMed ID: 22344701)
41. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
[TBL] [Abstract][Full Text] [Related]
42. In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms.
Xu L; Woodward C; Khan S; Prakash C
Drug Metab Dispos; 2012 Apr; 40(4):680-93. PubMed ID: 22217465
[TBL] [Abstract][Full Text] [Related]
43. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
44. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
[TBL] [Abstract][Full Text] [Related]
45. Development and validation of a fast and sensitive UPLC-MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity.
De Bock L; Boussery K; Colin P; De Smet J; T'jollyn H; Van Bocxlaer J
Talanta; 2012 Jan; 89():209-16. PubMed ID: 22284482
[TBL] [Abstract][Full Text] [Related]
46. Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824).
Cho YS; Whitehead L; Li J; Chen CH; Jiang L; Vögtle M; Francotte E; Richert P; Wagner T; Traebert M; Lu Q; Cao X; Dumotier B; Fejzo J; Rajan S; Wang P; Yan-Neale Y; Shao W; Atadja P; Shultz M
J Med Chem; 2010 Apr; 53(7):2952-63. PubMed ID: 20205394
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
Baertsch MA; Hillengass J; Blocka J; Schönland S; Hegenbart U; Goldschmidt H; Raab MS
Hematol Oncol; 2018 Feb; 36(1):210-216. PubMed ID: 28685863
[TBL] [Abstract][Full Text] [Related]
48. The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
Prince HM; Bishton M; Harrison S
Leuk Lymphoma; 2008 Mar; 49(3):385-7. PubMed ID: 18297514
[TBL] [Abstract][Full Text] [Related]
49. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
Chen Y; Wang X; Xiang W; He L; Tang M; Wang F; Wang T; Yang Z; Yi Y; Wang H; Niu T; Zheng L; Lei L; Li X; Song H; Chen L
J Med Chem; 2016 Jun; 59(11):5488-504. PubMed ID: 27186676
[TBL] [Abstract][Full Text] [Related]
50. Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.
Wang L; Syn NL; Subhash VV; Any Y; Thuya WL; Cheow ESH; Kong L; Yu F; Peethala PC; Wong AL; Laljibhai HJ; Chinnathambi A; Ong PS; Ho PC; Sethi G; Yong WP; Goh BC
Cancer Lett; 2018 Mar; 417():152-160. PubMed ID: 29306016
[TBL] [Abstract][Full Text] [Related]
51. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function.
Sharma S; Witteveen PO; Lolkema MP; Hess D; Gelderblom H; Hussain SA; Porro MG; Waldron E; Valera SZ; Mu S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):87-95. PubMed ID: 25377157
[TBL] [Abstract][Full Text] [Related]
52. Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.
Bat-Erdene A; Miki H; Oda A; Nakamura S; Teramachi J; Amachi R; Tenshin H; Hiasa M; Iwasa M; Harada T; Fujii S; Sogabe K; Kagawa K; Yoshida S; Endo I; Aihara K; Abe M
Oncotarget; 2016 Nov; 7(48):79064-79075. PubMed ID: 27738323
[TBL] [Abstract][Full Text] [Related]
53. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.
Wasim L; Chopra M
Biomed Pharmacother; 2016 Dec; 84():1393-1405. PubMed ID: 27802904
[TBL] [Abstract][Full Text] [Related]
54. Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Oanh DT; Hai HV; Park SH; Kim HJ; Han BW; Kim HS; Hong JT; Han SB; Hue VT; Nam NH
Bioorg Med Chem Lett; 2011 Dec; 21(24):7509-12. PubMed ID: 22036991
[TBL] [Abstract][Full Text] [Related]
55. HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2
Medon M; Vidacs E; Vervoort SJ; Li J; Jenkins MR; Ramsbottom KM; Trapani JA; Smyth MJ; Darcy PK; Atadja PW; Henderson MA; Johnstone RW; Haynes NM
Cancer Res; 2017 May; 77(10):2594-2606. PubMed ID: 28249907
[TBL] [Abstract][Full Text] [Related]
56. LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression.
Yao ZG; Li WH; Hua F; Cheng HX; Zhao MQ; Sun XC; Qin YJ; Li JM
J Neuropathol Exp Neurol; 2017 Dec; 76(12):1000-1007. PubMed ID: 29136455
[TBL] [Abstract][Full Text] [Related]
57. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
58. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
59. Discovery and extensive in vitro evaluations of NK-HDAC-1: a chiral histone deacetylase inhibitor as a promising lead.
Hou J; Li Z; Fang Q; Feng C; Zhang H; Guo W; Wang H; Gu G; Tian Y; Liu P; Liu R; Lin J; Shi YK; Yin Z; Shen J; Wang PG
J Med Chem; 2012 Apr; 55(7):3066-75. PubMed ID: 22435669
[TBL] [Abstract][Full Text] [Related]
60. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.
Dickinson M; Ritchie D; DeAngelo DJ; Spencer A; Ottmann OG; Fischer T; Bhalla KN; Liu A; Parker K; Scott JW; Bishton M; Prince HM
Br J Haematol; 2009 Oct; 147(1):97-101. PubMed ID: 19663825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
